Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun 1;23(6):872-873.
doi: 10.1093/neuonc/noab063.

Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?

Affiliations
Editorial

Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?

Franck Bourdeaut. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Haydar D, Houke H, Chiang J, et al. . Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery [published online ahead of print December 15, 2020]. Neuro Oncol. doi:10.1093/neuonc/noaa278. - DOI - PMC - PubMed
    1. Majzner RG, Theruvath JL, Nellan A, et al. . CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–2574. - PMC - PubMed
    1. Mount CW, Majzner RG, Sundaresh S, et al. . Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018;24(5):572–579. - PMC - PubMed
    1. Theruvath J, Sotillo E, Mount CW, et al. . Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med. 2020;26(5):712–719. - PMC - PubMed
    1. Du H, Hirabayashi K, Ahn S, et al. . antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221–237.e8. - PMC - PubMed

Substances